Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Marc Swanson

Pain Medicine Salem, VA Medical Doctor

NPI 1255350831 CMS profile 238470

100 Knotbreak Rd, Salem, VA 24153

Open in the dashboard

General payments

$7,546

346 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Marc Swanson of Salem, VA is reported in the CMS Open Payments database as having received $7,546 across 346 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,297 58
2022 General $1,362 73
2021 General $1,594 65
2020 General $1,437 71
2019 General $1,856 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Swanson
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Marc Swanson were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Marc Swanson Pain Medicine median Middle half National median
2019 $1,856 $498 $126–$1,682 $163
2020 $1,437 $284 $80–$910 $114
2021 $1,594 $399 $112–$1,219 $132
2022 $1,362 $455 $137–$1,484 $149
2023 $1,297 $484 $128–$1,495 $160
2024 $0 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Medtronic, Inc. $2,365 56 payments
  2. Medtronic USA, Inc. $2,048 73 payments
  3. Collegium Pharmaceutical, Inc. $676 63 payments
  4. AbbVie, Inc. $665 55 payments
  5. DePuy Synthes Sales Inc. $173 11 payments
  6. Amgen Inc. $160 10 payments
  7. Biodelivery Sciences International, Inc. $146 9 payments
  8. Teva Pharmaceuticals USA, Inc. $141 7 payments
  9. Allergan Inc. $121 8 payments
  10. Lilly USA, LLC $97 3 payments
  11. Other $954 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,528 343 payments
  2. Education $18 3 payments
Products named General payments · program years 2019–2023
  1. INTELLIS Spinal Cord Neurostimulation $1,455 57 payments
  2. Accurian $536 13 payments
  3. INTELLIS ADAPTIVESTIM $491 12 payments
  4. INTELLIS Spinal Cord Neurostimulation $482 12 payments
  5. UBRELVY $366 30 payments
  6. VANTA ADAPTIVESTIM $362 7 payments
  7. XTAMPZA $349 33 payments
  8. BELBUCA $309 27 payments
  9. QULIPTA $270 25 payments
  10. KYPHON EXPRESS II KYPHOPAK TRAY $184 5 payments
  11. Other $2,889 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

767

Median for Anesthesiology: 322

Drug cost

$17,721

Median for Anesthesiology: $8,738

Branded share of claims

30.2%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 189 $3,699
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 107 $2,968
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 68 $2,236
Fentanyl Generic 19 $2,077
Morphine Sulfate Er Morphine Sulfate Brand 57 $1,369
Pregabalin Generic 39 $1,081
Gabapentin Generic 73 $989
Hydromorphone Hcl Generic 29 $583
Morphine Sulfate Generic 11 $454
Tramadol Hcl Generic 21 $422

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Records

346 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record